Skip to main content
editorial
. 2016 Mar 21;22(11):3069–3077. doi: 10.3748/wjg.v22.i11.3069

Table 1.

Positive phase III trials of cytotoxic agents in second line metastatic cancers

Ref. Patients/phase Treatment Indication Results (PFS/OS/RR) (mo)
Ford et al[18], 2014 168/III Docetaxel Advanced, gastric cancer that had progressed on or within 6 mo of treatment with a platinum-fluoropyrimidine combination OS: 5.2
COUGAR-02 Active symptom control OS: 3.6
Kang et al[28], 2012[28] 202/III Docetaxel Advanced gastric cancer with one or two prior chemotherapy regimens involving both fluoropyrimidines and platinum 5.2
Irinotecan 6.5
BSC 3.8